UMCG Selects RayStation
News Sep 23, 2016
University Medical Center Groningen (UMCG) in the Netherlands has selected RayStation® as its treatment planning system. RayStation will replace the hospital’s existing system for conventional (photon) radiation therapy and will be the treatment planning system for its new proton therapy center. UMCG will have 30 clinical and 16 development licenses in total.
UMCG’s new proton therapy center, currently under construction, will be equipped with IBA’s ProteusPLUS two-gantry room configuration, including pencil beam scanning (PBS) and cone beam CT capabilities. UMCG anticipates the center will treat around 600 patients per year, with the first treatments taking place end of 2017.
The RayStation installation will include adaptive radiation therapy, multi-criteria optimization and radiobiology. In addition, a cluster computing platform will provide optimized performance for the Plan Explorer feature in RayStation. Plan Explorer automatically generates a large number of high-quality treatment plan alternatives, saving time and giving the clinician a wide range of options to consider.
UMCG will also be one of the first clinics in the world to implement RayCare®, a groundbreaking oncology information system currently in development at RaySearch. RayCare is designed to improve workflows across treatment techniques and to meet the demands of new techniques and approaches in cancer treatment.
Professor Hans Langendijk, chair of the Department of Radiation Oncology at UMCG, says: “Advanced techniques such as adaptive therapy and proton therapy demand software solutions that are equally cutting edge. We are a pioneer of radiation therapy in the Netherlands, and RaySearch is a partner that helps us improve treatment for all of our patients.”
Johan Löf, CEO of RaySearch, says: “UMCG is a leading clinic and I am delighted to be able to meet their treatment planning needs for both photon and proton therapy. Our longstanding research collaboration is important and will continue with the department’s early adoption of RayCare. Together we are pioneering the future of cancer care.”
SMi’s 5th Annual Molecular Diagnostics Conference 2018 Agenda ReleasedNews
SMi proudly presents its 5th annual conference on Molecular Diagnostics, taking place at the Holiday Inn Kensington Forum, London, UK on 9th and 10th July 2018, with a half-day post-conference workshops on 11th July 2018.READ MORE
Harvard Bioengineers’ Biomaterial-Based Cancer Immunotherapies to be Developed by NovartisNews
The Wyss Institute for Biologically Inspired Engineering at Harvard University and the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) announced today that Novartis will have access to commercially develop their therapeutic, biomaterial-based, cancer vaccine technology that promotes anti-cancer immunity.READ MORE